QURE
uniQure
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 6
Sell signal 0
stock price surged significantly
consensus rating "Strong Buy"
MACD Golden Cross
Upward Gap
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About QURE
Uniqure N.V.
A leading gene therapy company that develops innovative treatments for genetic diseases
Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands
--
UniQure N.V. was established as a private limited liability company on January 9, 2012 in accordance with the relevant provisions of the Dutch law. UniQure is a leader in the field of gene therapy and has developed the first and so far only gene therapy product that has received EU regulatory approval. Gene therapy provides long-term and potentially effective benefits to patients with genetic or acquired diseases, either by guiding the expression of therapeutic protein genes or by repairing the expression of deletion proteins through a single management. The company's first product, Glybera, was approved by the European Commission in October 2012 due to its excellent effect on patients with lipoprotein lipase deficiency (LPLD), a potentially life-threatening orphan metabolic disease.
Company Financials
EPS
QURE has released its 2024 Q4 earnings. EPS was reported at -1.49, versus the expected -0.54, missing expectations. The chart below visualizes how QURE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
QURE has released its 2024 Q4 earnings report, with revenue of 5.22M, reflecting a YoY change of -21.95%, and net profit of -73.26M, showing a YoY change of -0.08%. The Sankey diagram below clearly presents QURE’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
